Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Biogen Is Starting To Trend Higher (Technical Analysis)
03:19pm, Monday, 11'th Jul 2022
Biogen is beginning to have a trend change. Biogen is at the bottom of a trading range that goes back 10 years.
Stock Split Watch: Could Regeneron Be Next?
10:30am, Monday, 11'th Jul 2022 The Motley Fool
It's the highest-priced biotech stock.
How to fix the too-high 2022 Medicare Part B premium?
03:59pm, Friday, 08'th Jul 2022 MarketWatch
Midyear reductions and refunds don’t work; savings will be reflected in 2023 premium
7 Moonshot Investments Upending a $10 Trillion Industry
03:53pm, Friday, 08'th Jul 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on
Biohaven (BHVN) Begins Phase III Study on SMA Candidate
03:09pm, Friday, 08'th Jul 2022 Zacks Investment Research
Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.
Is This Biotech Stock a Bad News Buy?
02:00pm, Wednesday, 06'th Jul 2022 The Motley Fool
Things could get worse before they get better for this drugmaker.
Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's
01:15pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).
Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's
10:54am, Wednesday, 06'th Jul 2022
The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).
Alzheimer's Drug Is Up for Accelerated Approval. Outlook for Biogen, Eisai Is Uncertain.
09:04am, Wednesday, 06'th Jul 2022
The FDA will decide whether to approve lecanemab on the basis of early-stage data showing that it can clear brain plaques.
3 Biotech Stocks to Sell Now
02:16pm, Tuesday, 05'th Jul 2022
These biotech stocks remain vulnerable to more downside. Their charts remain broken and resistance looms ominously overhead.
FDA and drug makers deepen their commitment to clinical-trial diversity. Will it work?
04:34pm, Saturday, 02'nd Jul 2022 MarketWatch
After years of ‘lackluster’ efforts, regulators and companies are finally aligned in their goal to make clinical trials more representative of U.S. population.
Two-Minute Drill: JAZZ, BIIB & BABA
05:45pm, Wednesday, 29'th Jun 2022
Jessica Inskip, OptionsPlay director, joins ‘Closing Bell: Overtime' to give her favorite stock picks in this market, including Jazz Pharma, Biogen and Alibaba.
7 Biotech Stocks With Key Catalysts Coming in July
06:15am, Monday, 27'th Jun 2022
Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on Inv
Biogen stops clinical trial tracking Aduhelm
08:12am, Friday, 24'th Jun 2022
Biogen Inc. BIIB, +2.12% said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
01:32pm, Tuesday, 21'st Jun 2022 Zacks Investment Research
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
